Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 6/20 | 0.40 |
| ▸ | PDXK | O00764 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | S100A9 | P06702 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.33 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14809680 | 0.82 | PGK1 (0.39) | PDXKALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL23059362 | 0.81 | PDCD1 (0.40) | YTHDC1XDHPDE2AALDH1A1L3MBTL1 | |
| SCHEMBL22866260 | 0.80 | STK17B (0.39) | PDXKALDH1A1L3MBTL1KDM4EHPGD | |
| SCHEMBL15624865 | 0.79 | AGTR1 (0.41) | PDXKALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL30462033 | 0.79 | LMNA (0.41) | YTHDC1XDHPDE2AALDH1A1L3MBTL1 | |
| SCHEMBL26627803 | 0.79 | LMNA (0.41) | YTHDC1XDHPDE2AALDH1A1L3MBTL1 | |
| SCHEMBL24687844 | 0.79 | ALDH1A1 (0.47) | YTHDC1XDHPDE2AALDH1A1L3MBTL1 | |
| SCHEMBL18168128 | 0.78 | ESR1 (0.44) | PDXKALDH1A1L3MBTL1STK17BSTK17A | |
| SCHEMBL30891184 | 0.76 | ALDH1A1 (0.36) | YTHDC1XDHPDE2AALDH1A1L3MBTL1 | |
| SCHEMBL27153028 | 0.76 | ALDH1A1 (0.36) | YTHDC1XDHPDE2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115343-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| US-20200115343-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| US-10577329-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577329-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190202790-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190202790-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-10294206-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10294206-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180141910-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141910-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| WO-2016171755-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016171755-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160311774-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311774-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311774-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2694504-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | Afraxis Holdings, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2013043232-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311774-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | YTHDC1 2432/4885PDXK 899/4885XDH 395/4885 |
| US-20190202790-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | YTHDC1 2432/4885PDXK 899/4885XDH 395/4885 |
| US-10577329-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH3B | YTHDC1 2432/4885PDXK 899/4885XDH 395/4885 |
| US-20180141910-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | YTHDC1 2726/4885PDXK 866/4885XDH 416/4885 |
| US-10294206-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH3B | YTHDC1 2726/4885PDXK 866/4885XDH 416/4885 |
| US-20200115343-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | YTHDC1 2432/4885PDXK 899/4885XDH 395/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | YTHDC1 2789/4885PDXK 106/4885XDH 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.